ストックスクリーナーアプリを入手
8.00
3.43%
0.265
アフターアワーズ：
8.00
前日終値:
$7.735
開ける：
$7.63
24時間の取引高:
1.34M
Relative Volume:
1.45
時価総額：
$569.36M
収益：
$133.62M
当期純損益:
$-177.37M
株価収益率:
-2.7682
EPS:
-2.89
ネットキャッシュフロー:
$23.50M
1週間 パフォーマンス:
+5.68%
1か月 パフォーマンス:
-24.39%
6か月 パフォーマンス:
-68.75%
1年 パフォーマンス:
-66.51%
1日の値動き範囲:
$7.34
$8.055
1週間の範囲:
$7.34
$8.055
52週間の値動き範囲:
$7.16
$27.24
Xencor Inc Stock (XNCR) Company Profile
XNCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
8.00 | 538.76M | 133.62M | -177.37M | 23.50M | -2.89 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2024-12-12 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 繰り返されました | BTIG Research | Buy |
| 2024-02-28 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 開始されました | BofA Securities | Buy |
| 2022-12-06 | 開始されました | Cowen | Outperform |
| 2022-10-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-21 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-02-24 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 開始されました | Barclays | Underweight |
| 2020-02-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-01-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-11-20 | 再開されました | Guggenheim | Neutral |
| 2019-08-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-04-12 | 開始されました | Guggenheim | Buy |
| 2019-03-27 | 開始されました | Berenberg | Buy |
| 2019-03-15 | 開始されました | Raymond James | Outperform |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2017-03-02 | 開始されました | Instinet | Neutral |
| 2017-03-02 | 繰り返されました | Wedbush | Outperform |
| 2016-10-04 | 開始されました | Piper Jaffray | Overweight |
| 2015-12-22 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-05 | 繰り返されました | MLV & Co | Buy |
| 2015-02-12 | 繰り返されました | Oppenheimer | Outperform |
| 2015-01-28 | 繰り返されました | MLV & Co | Buy |
| 2014-07-11 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Xencor Inc (XNCR) 最新ニュース
Xencor Inc (NASDAQ: XNCR) Jumps 2.45%: What Could Be On The Way Going Forward? - Stocksregister
Xencor’s SWOT analysis: biotech stock faces pivotal year amid pipeline progress - Investing.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $929,000 Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Where are the Opportunities in (XNCR) - news.stocktradersdaily.com
BNP Paribas Financial Markets Purchases 3,171 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (NASDAQ:XNCR) Holdings Lowered by Jane Street Group LLC - Defense World
Deutsche Bank AG Buys 20,128 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor, Inc. (XNCR) Stock Analysis: Exploring a Potential 266% Upside in Biotech Investments - DirectorsTalk Interviews
Ameriprise Financial Inc. Has $6.72 Million Stake in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Life Sciences Companies Have New Avenue to Challenge Patent Applications After Federal Court Ruling - JD Supra
Xencor, Inc. (NASDAQ:XNCR) Position Boosted by Comerica Bank - Defense World
Xencor Inc. Reports Revenue Growth Amidst Ongoing R&D Investments - TipRanks
Northern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Investor Network: Xencor, Inc. to Host Earnings Call - ACCESS Newswire
Xencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA) - The Globe and Mail
Leerink Partnrs Has Bearish Forecast for Xencor Q2 Earnings - Defense World
Wedbush Comments on Xencor’s Q2 Earnings (NASDAQ:XNCR) - Defense World
Research Analysts Set Expectations for Xencor Q2 Earnings - Defense World
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating - Investing.com Nigeria
Q4 Earnings Forecast for Xencor Issued By William Blair - Defense World
What is Wedbush’s Estimate for Xencor Q4 Earnings? - Defense World
Barclays Issues Pessimistic Forecast for Xencor (NASDAQ:XNCR) Stock Price - Defense World
Xencor Inc earnings missed by $0.04, revenue topped estimates - Investing.com Nigeria
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Bar - GuruFocus
Xencor (XNCR) Analyst Rating Update: Price Target Slashed by Barclays | XNCR Stock News - GuruFocus
JPMorgan cuts Xencor stock price target to $20, keeps overweight rating By Investing.com - Investing.com South Africa
Xencor Reports First Quarter 2025 Financial Results - BioSpace
Xencor: Q1 Earnings Snapshot - MySA
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
(XNCR) Technical Data - news.stocktradersdaily.com
Xencor (NASDAQ:XNCR) Earns Outperform Rating from Wedbush - Defense World
Healthy Upside Potential: Xencor Inc (XNCR) - Sete News
Xencor reports positive trial results for inflammatory bowel disease treatment - MSN
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Wells Fargo & Company MN Raises Stock Holdings in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Analyzing Xencor Inc (XNCR) After Recent Trading Activity - knoxdaily.com
Trading Day Triumph: Xencor Inc (XNCR) Ends at 10.58, a -0.19 Surge/Plunge - DWinneX
Is Xencor Inc (XNCR) a good investment opportunity? - uspostnews.com
Xencor, Inc. to Host Earnings Call - ACCESS Newswire
Xencor Announces Promising Phase 1 Study Results - TipRanks
Raymond James Financial Inc. Invests $2.33 Million in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor (XNCR) Reports Promising Results and Advances XmAb942 Stu - GuruFocus
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - BioSpace
Xencor posts trial data for bowel disease drug (XNCR:NASDAQ) - Seeking Alpha
Xencor advances ulcerative colitis treatment into Phase 2b study - Investing.com
Xencor (XNCR) Reports Promising Results and Advances XmAb942 Study | XNCR Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Xencor Inc (XNCR) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):